资讯

Clinical Trials Arena on MSN7 天
AstraZeneca and Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...
腾讯网7 天
首次！重磅ADC临床3期结果优于标准疗法；胆固醇降幅超80%！体内基因 ...
CRISPR ...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) announce that Enhertu hit the main goal in a Phase 3 trial for early-stage ...
Fierce Pharma7 天
AstraZeneca, Daiichi Sankyo's Enhertu rings up success in another breast cancer trial
Less than three weeks after AstraZeneca and Daiichi Sankyo reported positive results for oncology powerhouse Enhertu in a ...
【阿斯利康】公布乳腺癌治疗临床试验积极结果
阿斯利康（AstraZeneca PLC）于周三宣布，其最新试验评估的Enhertu在高风险、局部晚期HER2阳性早期乳腺癌患者中获得了积极的高水平结果。该公司表示，Destiny-Breast11三期试验显示，Enhertu（trastuzumab deruxtecan）联合使用紫杉醇、曲妥珠单抗和帕妥珠单抗，较现行标准治疗在病理完全缓解率上实现了统计学和临床上显著的改善。 Enhertu由阿斯 ...
PMLive7 天
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...
The Pharma Letter8 天
AstraZeneca and Daiichi push Enhertu into earlier breast cancer use
UK-based pharma major AstraZeneca and its Japanese partner Daiichi Sankyo are moving to expand the reach of their blockbuster ...
Yahoo Finance7 天
AstraZeneca, Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
Clinical Trials Arena · Jo Panuwat D/Shutterstock. AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan), followed by paclitaxel, trastuzumab and pertuzumab (THP), has shown ...
pharmaphorum8 天
New data could move Enhertu into early breast cancer
AstraZeneca and Daiichi Sankyo's anti-HER2 drug Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage ...
AstraZeneca receives 'positive high-level results' results from Enhertu trial
Drugmaker AstraZeneca revealed on Wednesday that it had received "positive high-level results" from a Phase III trial on its ...
Health And Pharma8 天
Enhertu Plus THP Outperforms Standard Chemotherapy in High-Risk, Early-Stage HER2+ Breast ...
The Phase III DESTINY-Breast11 trial showed Enhertu followed by THP significantly improved pathologic complete response (pCR) ...
PharmiWeb8 天
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety ...
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of careFirst Phase III trial to demonstrate benefit of Enhertu in early breast cancer Positive ...